Karyopharm Therapeutics (KPTI) PT Lowered to $6 at Wedbush, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KPTI Hot Sheet
Price: $0.07 --0%
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 2
Rating Summary:
10 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 2
Join SI Premium – FREE
Wedbush analyst David Nierengarten lowered the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $6.00 (from $11.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rodman & Renshaw Downgrades Karyopharm Therapeutics (KPTI) to Neutral
- Newmont Corp (NEM:AU) (NEM) PT Raised to AUD170.40 at Goldman Sachs
- Karyopharm files for Chapter 11, names Ayrmid as merger partner
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
